Innovative Drug Pipeline Tosk is actively developing advanced cancer therapies, including drugs targeting critical genetic drivers like KRAS, presenting opportunities to collaborate or supply specialized manufacturing and formulation services to accelerate clinical trials.

Recent Product Milestone With TK-90 successfully completing Phase 2 studies for head and neck cancer, there is potential to promote post-approval manufacturing, distribution, and clinical support solutions tailored to oncology products.

Strong Funding and Grants Tosk has secured $2 million in grants from the NCI and $1.3 million in private funding, indicating both government and investor confidence, opening doors for strategic partnerships or additional investment opportunities.

Expert Advisory Team The addition of leading cancer pharmacology and oncology side effect experts to Tosk’s advisory boards highlights a focus on cutting-edge research, which could benefit from specialized technology, analytical tools, or contract research services.

Growth and Expansion Potential As a small company with significant research achievements and upcoming clinical milestones, Tosk presents opportunities for early-stage collaborations, contract manufacturing, or licensing deals to support their pipeline's advancement.